Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Gilead Sciences, Inc.
Gilead Sciences, Inc. News
Gilead Sciences, Inc. Quantitative Score
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Gilead Sciences, Inc. Financials
Table Compare
Compare GILD metrics with: | |||
|---|---|---|---|
Earnings & Growth | GILD | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GILD | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GILD | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GILD | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Gilead Sciences, Inc. Income
Gilead Sciences, Inc. Balance Sheet
Gilead Sciences, Inc. Cash Flow
Gilead Sciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Gilead Sciences, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 3.1600 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-12-30 | 0.79 | Quarterly |
| 2025-09-29 | 0.79 | Quarterly |
| 2025-06-27 | 0.79 | Quarterly |
| 2025-03-28 | 0.79 | Quarterly |
| 2024-12-30 | 0.77 | Quarterly |
Historical Market Cap
Shares Outstanding
Gilead Sciences, Inc. Executives
| Name | Role |
|---|---|
| Daniel O'Day | Chairman & Chief Executive Officer |
| Johanna Mercier | Chief Commercial Officer |
| Deborah H. Telman | Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary |
| Andrew D. Dickinson | Chief Financial Officer |
| Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Daniel O'Day | Chairman & Chief Executive Officer | Male | 1965 | 7.14M |
| Johanna Mercier | Chief Commercial Officer | Female | 1970 | 3.17M |
| Deborah H. Telman | Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary | Female | 1965 | 3.11M |
| Andrew D. Dickinson | Chief Financial Officer | Male | 1970 | 2.73M |
| Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio | 1962 | -- |
Gilead Sciences, Inc. Insider Trades
| Date | 15 Dec |
| Name | Dickinson Andrew D |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3000 |
| Date | 15 Dec |
| Name | Mercier Johanna |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3000 |
| Date | 10 Dec |
| Name | Dickinson Andrew D |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 3693 |
| Date | 10 Dec |
| Name | Dickinson Andrew D |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 1745 |
| Date | 10 Dec |
| Name | Dickinson Andrew D |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 3693 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Dec | Dickinson Andrew D | Chief Financial Officer | Disposed | S-Sale | 3000 |
| 15 Dec | Mercier Johanna | Chief Commercial Officer | Disposed | S-Sale | 3000 |
| 10 Dec | Dickinson Andrew D | Chief Financial Officer | Acquired | M-Exempt | 3693 |
| 10 Dec | Dickinson Andrew D | Chief Financial Officer | Disposed | F-InKind | 1745 |
| 10 Dec | Dickinson Andrew D | Chief Financial Officer | Disposed | M-Exempt | 3693 |